Strategies for inhibitor treatment and costs in the short and long term: a critical evaluation of recent clinical studies
Baghaipour, Mohammad Reza and Steen Carlsson, Katarina LU
(2015)
In European Journal of Haematology
94.
p.30-37
- Abstract
- One important complication of patients with severe haemophilia A is the formation of inhibitory antibodies to factor VIII (FVIII). Immune tolerance induction (ITI) is the treatment of choice for patients with inhibitors, but this approach is successful in about 60% of patients. Treatment of acute bleeding in patients with inhibitors is one of the greatest challenges in haemophilia management and is costly. Bypassing agents are the mainstay of treatment in these patients. The aims of this study were to review the most recent publications concerning the costs of inhibitor treatment. We conducted a literature review using PubMed which yielded 63 papers analysing the costs of inhibitor management of which 12 were suitable for our study. Four... (More)
- One important complication of patients with severe haemophilia A is the formation of inhibitory antibodies to factor VIII (FVIII). Immune tolerance induction (ITI) is the treatment of choice for patients with inhibitors, but this approach is successful in about 60% of patients. Treatment of acute bleeding in patients with inhibitors is one of the greatest challenges in haemophilia management and is costly. Bypassing agents are the mainstay of treatment in these patients. The aims of this study were to review the most recent publications concerning the costs of inhibitor treatment. We conducted a literature review using PubMed which yielded 63 papers analysing the costs of inhibitor management of which 12 were suitable for our study. Four of eight studies supported the use of activated prothrombin complex concentrate (aPCC) with lower costs, but the remaining four studies showed that recombinant factor VIIa (rFVIIa) had a lower average treatment cost. Of four ITI studies, two supported lifelong cost-effectiveness of ITI vs. bypassing agents and the remaining two papers showed a high cost of inhibitor treatment. Dosages, time between onset of bleeding and treatment, patient characteristics and the price of drugs are some of the important issues that should be considered for further studies. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5076005
- author
- Baghaipour, Mohammad Reza
and Steen Carlsson, Katarina
LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- haemophilia, costs, inhibitors, clinical studies, bypassing agents
- in
- European Journal of Haematology
- volume
- 94
- pages
- 30 - 37
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000347371100007
- scopus:84920274917
- pmid:25560792
- ISSN
- 1600-0609
- DOI
- 10.1111/ejh.12499
- language
- English
- LU publication?
- yes
- id
- 90157bfe-6747-4631-8b30-1d6d6745b2c7 (old id 5076005)
- date added to LUP
- 2016-04-01 10:04:31
- date last changed
- 2023-10-25 23:51:39
@article{90157bfe-6747-4631-8b30-1d6d6745b2c7,
abstract = {{One important complication of patients with severe haemophilia A is the formation of inhibitory antibodies to factor VIII (FVIII). Immune tolerance induction (ITI) is the treatment of choice for patients with inhibitors, but this approach is successful in about 60% of patients. Treatment of acute bleeding in patients with inhibitors is one of the greatest challenges in haemophilia management and is costly. Bypassing agents are the mainstay of treatment in these patients. The aims of this study were to review the most recent publications concerning the costs of inhibitor treatment. We conducted a literature review using PubMed which yielded 63 papers analysing the costs of inhibitor management of which 12 were suitable for our study. Four of eight studies supported the use of activated prothrombin complex concentrate (aPCC) with lower costs, but the remaining four studies showed that recombinant factor VIIa (rFVIIa) had a lower average treatment cost. Of four ITI studies, two supported lifelong cost-effectiveness of ITI vs. bypassing agents and the remaining two papers showed a high cost of inhibitor treatment. Dosages, time between onset of bleeding and treatment, patient characteristics and the price of drugs are some of the important issues that should be considered for further studies.}},
author = {{Baghaipour, Mohammad Reza and Steen Carlsson, Katarina}},
issn = {{1600-0609}},
keywords = {{haemophilia; costs; inhibitors; clinical studies; bypassing agents}},
language = {{eng}},
pages = {{30--37}},
publisher = {{Wiley-Blackwell}},
series = {{European Journal of Haematology}},
title = {{Strategies for inhibitor treatment and costs in the short and long term: a critical evaluation of recent clinical studies}},
url = {{http://dx.doi.org/10.1111/ejh.12499}},
doi = {{10.1111/ejh.12499}},
volume = {{94}},
year = {{2015}},
}